Treatment Benefits of Flavonoids Quercetin and Curcumin Supplements for Mild Symptoms of COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Testing negative for SARS-CoV-2 by Reverse Transcription Polymerase Chain Reaction (RT-PCR)
研究概览
简要总结
The purpose of this study is to investigate the therapeutic benefits of flavonoids nutritional supplements quercetin and curcumin for early mild symptoms of COVID-19.
详细描述
Flavonoids nutritional supplements quercetin and curcumin have demonstrated strong antioxidant, broad-spectrum anti-viral and anti-inflammatory properties including against the respiratory tract infections. They are widely used to boost the immunity against infections and keeping healthy life-style. Results from recent published studies have shown positive results for quercetin and curcumin in patients with COVID-19.
In the present study the investigators aim to study the combined beneficial effects of quercetin and curcumin in addition to standard of care for managing early mild symptoms of COVID-19 in community-based patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be 18 years of age or older, of either gender
- •Patients must be tested positive for SARS-CoV-2 by RT-PCR
- •Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes withshaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.
- •Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening
- •Patients must be under the care of a Physician for diagnosis of COVID-19
- •Patients who have signed informed consent
排除标准
- •Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin
- •Patients with known chronic kidney disease with estimated creatinine clearance < 50 mL/minute or need for dialysis
- •Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure
- •Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin.
- •Patients with gallstone obstruction
- •Hypothyroid suppering patients
- •Patients with moderate or severe thrombocytopenia (platelet count <100 ×10⁹/L);
- •Pregnant patients
研究组 & 干预措施
Standard of care
This arm will receive the standard of care as per the hospital guidelines.
干预措施: Standard of care (Drug)
Investigational treatment
This arm will receive combination of nutritional supplements quercetin and curcumin as add-on to the standard of care.
干预措施: Standard of care (Drug)
Investigational treatment
This arm will receive combination of nutritional supplements quercetin and curcumin as add-on to the standard of care.
干预措施: Investigational treatment (Dietary Supplement)
结局指标
主要结局
Testing negative for SARS-CoV-2 by Reverse Transcription Polymerase Chain Reaction (RT-PCR)
时间窗: Day 7
Testing of naso-pharyngeal swab for COVID-19
COVID-19 symptoms improvement
时间窗: Day 7
Improvement of the typical symptoms associated with COVID-19 infection
次要结局
- Improvement in CRP level(Day 7)
- Improvement in D-dimers level(Day 7)
- Improvement in LDH levels(Day 7)
- Improvement in ferritin levels(Day 7)
- Improvement in full blood count (CBC)(Day 7)
研究者
somia iqtadar
Associate Professor of Medicine
King Edward Medical University